GlassScriptPhysician profile
Amanda Mazzetta
NPI 1801048103
$3,971.41
in general payments reported to CMS, 2019-2025
31 companies · $1,086 in 2025
The $1,086 reported for 2025 was more than what 82% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $636 · 2022: $289 · 2023: $830 · 2024: $1,130 · 2025: $1,086.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,752 · Education: $294.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,752.16 |
| Education | $294.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $809.83 | 2021-2025 | Dupixent, Libtayo |
| Janssen Biotech, INC. | $336.70 | 2021-2024 | Tremfya, Simponi Aria, Remicade |
| Sun Pharmaceutical Industries INC. | $277.58 | 2021-2025 | Blu-U, Odomzo, Ilumya |
| Incyte Corporation | $260.17 | 2022-2025 | Opzelura |
| Pfizer INC. | $236.58 | 2021-2025 | |
| Lilly USA, LLC | $216.68 | 2023-2024 | Taltz, Ebglyss, Olumiant |
| Ucb, INC. | $200.60 | 2021-2024 | Bimzelx, Cimzia |
| Abbvie INC. | $194.53 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $166.62 | 2021-2025 | |
| Botanix Sb INC | $156.88 | 2025 | Sofdra |
| E.R. Squibb & Sons, L.L.C. | $150.07 | 2023-2024 | Sotyktu |
| Leo Pharma INC. | $130.63 | 2021-2025 | Anzupgo, Adbry |
| Genzyme Corporation | $110.74 | 2021-2024 | |
| Mayne Pharma Commercial LLC | $106.10 | 2023-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $78.87 | 2021-2024 | Jublia, Cabtreo, Arazlo |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $68.67 | 2023-2024 | Vtama |
| Galderma Laboratories, L.P. | $67.62 | 2024 | |
| Amgen INC. | $60.11 | 2021-2023 | Otezla |
| Verrica Pharmaceuticals INC. | $49.59 | 2023-2024 | Ycanth |
| Almirall LLC | $47.71 | 2021-2025 | Klisyri |
| Vyne Pharmaceuticals INC. | $40.76 | 2021 | |
| Convatec INC. | $35.00 | 2024-2025 | |
| Arcutis Biotherapeutics, INC. | $29.63 | 2024 | Zoryve |
| Organogenesis INC. | $25.90 | 2024 | |
| Epi Health, LLC | $23.70 | 2021-2022 | |
| Helsinn Therapeutics (U.S.), INC. | $23.02 | 2025 | Valchlor |
| Celgene Corporation | $17.79 | 2024 | Sotyktu |
| Journey Medical Corporation | $17.59 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.39 | 2023 | Spevigo |
| Mission Pharmacal Company | $12.38 | 2021 | |
| Organon LLC | $5.97 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Mazzetta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.